About Enzychem Lifesciences
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18 (Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications. The company is also developing EC-18 in fibrotic diseases such as nonalcoholic steatohepatitis (NASH), and in severe respiratory diseases as a potential therapy for COVID-19. EC-18, or PLAG, is a naturally synthesized substance, derived from an active ingredient in Sika deer antlers. Our pipeline candidates have the potential to be first-in-class therapies for use in combination or as monotherapy, in major areas of unmet medical need.
Our Vision
To Improve the Lives of Patients with
Cancer and Inflammatory Diseases
Developing first-in-class small
molecules to target
fundamental
inflammation pathways
History
2025
OCTOBER
Obtained Foreign Manufacturer Accreditation for Pharmaceuticals in Japan(AFM)
MAY
Registered U.S. patent for novel immunomodulatory compound targeting inflammatory immune diseases (glycerol derivative-based)
MAY
Published Phase 2 clinical trial results for oral mucositis treatment in Cancers
APRIL
Opened the AI Mobility Bio Lab (AMBL)
FEBRUARY
Registered U.S. substance patent for new immunomodulator (1,2-diacylglycerol compound)
2024
OCTOBER
Publication of non-clinical research results for Atopic Dermatitis in Scientific Reports(SCI)
OCTOBER
Publication of non-clinical research results for Gastrointestinal Acute Radiation Syndrome(GI-ARS) in Radiation Research(SCI)
OCTOBER
Korea MFDA approved IND for clinical phase 2 of atopic dermatitis
AUGUST
Publication of non-clinical research results for anti-cancer efficacy in Non Small Cell Lung Cancer(NSCLC) in Biomidicine & Pharmacotherapy(SCI)
2023
JULY
Announced EL Group Vision
JANUARY
Acquisition of Shinhung Bio energy
JANUARY
Completed renovation of Jecheon Plant 1
2022
JUNE
Presented phase 2 research results on oral mucositis at the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC) meetings
APRIL
Presentation of PLAG’s anti-cancer efficacy and side effect alleviation research results at the Annual Meeting of the American Association for Cancer Research (AACR)
2021
NOVEMBER
pDNA Vaccine Partnership with Zydus Cadila
OCTOBER
CRIOM Phase 2 Study Successfully Completed
SEPTEMBER
CRIOM Phase 2 Stage 2 Database Lock Completed
JUNE
International Liver Congress 2021 (EASL) Presentation of First in-class, Orally Active TLR Signaling Inhibitor Mosedipimod Attenuates Molecular, Biochemical and Histologic Features of NASH in vitro and in vivo
MAY
NASH-TAG Conference Presentation of TLR Signaling Inhibition with Mosedipimod
Keystone Symposia Poster Presentation of DAMP/Toll-like Receptor Signaling Attenuation with Mosedipimod: Effect in vitro and in two animal models of NASH
APRIL
AACR Poster Presentation of Suppressive Effect of PLAG on Tumor Progression and its Synergistic Therapeutic Effect with ICI therapy through Adenosine Clearance
CRIOM Phase 2 Stage 2 Patient Enrollment Completed
MOU for Research Collaboration on Space Health Solution with Inha University
JANUARY
NASA Grant Funding Received to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space
2020
OCTOBER
Two RRS Presentations of EC-18’s Efficacy as ARS Treatment
SEPTEMBER
ESMO Presentation of Synergistic PD-1 Antibody Anticancer Effect of EC-18 on Lung Cancer
AUGUST
COVID-19 Phase 2 IND US FDA Approval
JUNE
AACR Presentation of Synergistic PD-L1 Antibody Anticancer Effect of EC-18 on Bladder Cancer and EC-18’s Efficacy in CRIOM
MAY
COVID-19 Phase 2 IND Korea MFDS Approval
1st Evaluation of the Space Radiation Treatment Development Project Passed by NASA
JANUARY
Biotech Showcase Company Presentation
2019
DECEMBER
AFRRI and DoD Collaboration for EC-18 as Radiation Medical Countermeasure
NOVEMBER
AASLD Presentation for EC-18 Efficacy in NASH
OCTOBER
AACR-NCI-EORTC Conference Presentation of EC-18 in Anti-Cancer and Anti-Metastasis Effect and CIN Phase 2 Part 1 Study Results
MAY
ARS Phase 2 Multi-Animal Studies FDA Approval
CIN Phase 2 Stage 1 Study Completed
FEBRUARY
CRIOM Phase 2 Stage 1 Patient Enrollment Study Completed
EU GMP Approved
JANUARY
RNCP and CCRP’s support selected by NIH NIAID
2018
JUNE
Enzychem Lifesciences USA, Inc Established and Global Operation Launched
MARCH
Fast Track Designation by US FDA on CRIOM
FEBRUARY
Listed on the KOSDAQ Stock Market (KOSDAQ: 183490)
2017
DECEMBER
Orphan Drug Designation by US FDA on ARS
JULY
CRIOM Phase 2 IND US FDA Approval
MAY
AAI Presentation
2016
DECEMBER
CIN Phase 2 IND Korea MFDS Approval
NOVEMBER
3rd KDDF Government Grant for Global New Drug Development Awarded
JULY
CIN Phase 2 IND US FDA Approval
MAY
AAI Annual Meeting Presentation
2015
OCTOBER
2nd KDDF Government Grant for Global New Drug Development Awarded
MAY
CIN Phase 1 IND Approved by US FDA
MARCH
GMP Qualification Approved by Japan PMDA
FEBRUARY
1st KDDF Government Grant for Global New Drug Development Awarded
JANUARY
Pharm Navi Selected by Korea MFDS
New Technology Product Selected by the Korea MOTIE
2014
SEPTEMBER
CIN Investigators Initiated Study Completed at Asan Medical Center
JULY
EC-18 Approved IND by Korea MFDS
2013
SEPTEMBER
Listed on the KONEX Stock Market
JANUARY
Plant 2 Certified for GMP by Korea MFDS
1st Human Clinical Trial for EC-18 Conducted by Myung-Ji Hospital of Kwandong University
2011
JUNE
New Health Technology Certification Acquired from KHIDI
MARCH
Columbus Project Company through the Korea MOHW
FEBRUARY
Successful Commercial Production of EC-18
2009
APRIL
Plant Inspection Completed by Otto Brands GmbH, Hamburg, Germany for D – Cycloserine Production
2008
APRIL
Plant 1 Certified for GMP by Korea MFDS
2007
MARCH
INNOBIZ Certification Awarded by SMBA
2004
NOVEMBER
"Tower of Million-Dollar Export" Awarded by Korea MOTIE
2000
MARCH
Korea Good Technology Mark Acquired by Korea MEST
1999
JULY
Enzychem Lifesciences is Founded